King Altace HOPE Study Reprint Announcement Draws Objection From FDA

An FDA ad division letter to King Pharmaceuticals regarding promotion of the HOPE cardiovascular outcomes study of Altace (ramipril) suggests the limits that the agency will put on promotion of new indications for the drug.